A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.
A phase III win for Roche’s satralizumab has added to Alexion’s Soliris woes.
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.